MDM2 and hypophosphatemia: Its common adverse events include anemia, leukopenia, pancytopenia, nausea, hyperbilirubinemia, hypophosphatemia, and anorexia.1063 A phase I trial of MK-8242 in patients with refractory/recurrent AML has been completed.1064 Furthermore, Milademetan (DS3032b) is an orally active MDM2 inhibitor by disrupting the MDM2-p53 interaction.1065 A phase I study of milademetan in combination with low-dose cytarabine with or without venetoclax for the treatment of AML has been completed, and has revealed modest therapeutic responses with recognizable gastrointestinal toxicity.1065